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Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, BelgiumAbstractDuring 12 years of surveillance in Belgium, dengue virus (DENV) infection was diagnosed in 676 of 7771 (8.7%) returning travellers by the use
of ELISA, RT-PCR, and/or antigen detection. Men and women were equally infected. The mean age of the patients was 36.78 years (range,
3–77 years). Most of the infections occurred after a stay in Asia (55.9%), followed by the Americas (31.8%), Africa (7.2%), Oceania (1.0%),
and Europe (0.4%). The number of patients coming from Africa increased as of 2009, to reach a proportion of 17% in 2011. The most
prevalent serotype was DENV-1, followed by DENV-2, DENV-3, and DENV-4. Two remarkable increases in dengue incidence were
noticed in 2010 and 2013.
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E-mail: mvesbroeck@itg.beIntroductionDengue viruses (DENVs) are RNA viruses belonging to the
genus Flavivirus. Four different serotypes (DENV-1 to DENV-4)
are transmitted between humans through vectors of the Aedes
family [1]. Dengue fever is the most important arboviral disease
in humans. Recent research has indicated that 390 million
DENV infections occur annually, of which 96 million manifest
apparently [2]. Travel and trade have played an important role,
as they have introduced both the vectors and the pathogen to
new areas of the world.
In recent decades, dengue fever in Europe was restricted to
imported infections. In 2010, the ﬁrst two autochthonous
dengue cases since the outbreak in Greece in 1927–1928 were
diagnosed in the south of France [3], and autochthonous casesClinical Microbiology and Infection © 2015 European Society of Chave been reported since then in Croatia in 2010 [4] and
France in 2013 [5]. In 2012, an outbreak of dengue fever was
reported in Madeira, Portugal [6].
In this study, the surveillance of DENV infections in Belgium
in the period 2002–2013 is described.Materials and methodsPatients
Blood samples were obtained from travellers and immigrants
presenting at the Institute of Tropical Medicine (ITM), Antwerp,
Belgium, housing an outpatient clinic, or were sent for diagnosis
or conﬁrmation by other Belgian laboratories and hospitals to
the ITM in its capacity as a national reference centre.
Serology
Detection of DENV IgM antibodies was performed with the
Dengue IgM capture ELISA test (PanBio Diagnostics, Windsor,
Queensland, Australia) until March 2007, and with the Dengue
Virus IgM Capture Dx Select (Focus Diagnostics, Cypress, CA,
USA) thereafter. DENV IgG antibodies were detected with anClin Microbiol Infect 2015; 21: 867–872
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infected with DENV-1, DENV-2 and DENV-4 until March 2004,
with the Dengue IgG capture ELISA test (PanBio Diagnostics)
from March 2004 to June 2009, and with the Dengue Virus IgG
Dx Select (Focus Diagnostics) thereafter.
Real-time RT-PCR
Real-time RT-PCR was introduced in the laboratory in 2010,
and was performed as described previously [7]. PCR was
initially used to determine the DENV serotype retrospectively
in acute-phase serum samples (8 days after symptom onset)
from patients who showed seroconversion of antibodies in a
follow-up sample. From 2011 onwards, PCR was performed
prospectively on acute-phase serum samples when requested
by the physician or the laboratory responsible.
Antigen detection
As of September 2011, detection of the non-structural protein-
1 (NS1) antigen (SD Bioline Dengue NS1 Ag; Standard Di-
agnostics, Yongin-si, Korea) was introduced in the laboratory to
allow for rapid diagnosis of acute DENV infections. All samples
examined by antigen detection were also analysed by PCR.
The clinical laboratory of the ITM is accredited according to
ISO15189:2007, for DENV IgM and IgG ELISA as of 2004 and
2006, respectively, for DENV RT-PCR as of 2011, and for NS1
antigen detection as of 2012.
Retrieval of epidemiological and clinical data
The travel history and limited clinical data of patients with an
indication of a DENV infection based on the laboratory results
were obtained from the medical patient ﬁle for ITM patients,FIG. 1. Annual number of dengue virus infections, distribution per travel de
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectand from a questionnaire sent to or by direct contact with
colleagues from the referring laboratory for patients receiving
medical care outside the ITM. The clinical information was used
to support the laboratory diagnosis. The countries were clas-
siﬁed according to the United Nations geographical regions
deﬁnition.
Diagnosis
There is no national Belgian case deﬁnition. Diagnosis was
established when DENV RNA and/or NS1 antigen were
detected, when IgM and/or IgG seroconversion or a four-fold
rise in IgG antibody titre was detected in paired serum sam-
ples, and/or when speciﬁc IgM antibodies were present in a
single serum sample according to the WHO case deﬁnitions
[8].
Ethical aspects
According to ITM policy, approved by the Institutional Review
Board, leftover samples of patients presenting at the ITM can be
used for research as long as the patient’s identity is not dis-
closed to third parties and the patient does not explicitly state
an objection.ResultsOver the period 2002–2013, a total of 8972 serum samples
from 7771 patients were analysed. Before 2010, between 450
and 637 samples were analysed annually, and this number
increased to 951, 918, 1293 and 1413 in 2010, 2011, 2012 and
2013, respectively. Whereas the number of analyses performedstination and annual positivity rate for the period 2002–2013.
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 867–872
FIG. 2. Age distribution of dengue virus infections per year for the
period 2002–2013.
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during the whole study period, varying between 261 and 492,
with a mean of 363, the number of samples sent by external
laboratories increased steadily, from 173 in 2002 to 975 in
2013. A DENV infection was diagnosed in 676 (8.7%) of the
patients with serological ﬁndings (n = 663), PCR ﬁndings
(n = 97) and/or NS1 antigen detection (n = 38). For 24 patients
(3.6%), no clinical information was available to support the
laboratory results. The number of dengue cases per year and
the annual positivity rate are shown in Fig. 1. Men and women
were equally infected (male/female ratio of 1: 1) (data notFIG. 3. Overall seasonal distribution of dengue virus infections and seasona
2002–2013.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyshown). The mean age of the patients was 36.78 years (range,
3–77 years). The age of two patients was unknown. The age
distribution is shown in Fig. 2. The 20–29-year and 30–39-year
age groups were most affected. The overall seasonal variation
and the seasonal variation for the continents Asia, America and
Africa are shown in Fig. 3. Dengue cases peaked in August and
September, mostly because of increases in the numbers of
people returning from Asia and, to a lesser extent, the Amer-
icas. The distribution of the travel destinations over the years is
shown in Fig. 1 (a detailed list is given in Table S1). Most patients
travelled to Asia (n = 378, 55.9%), followed by the Americas
(n = 215, 31.8%), Africa (n = 49, 7.2%), Oceania (n = 7, 1.0%),
and Europe (n = 3, 0.4%). The destinations of 24 patients (3.6%)
remained unknown. The overall top three destinations were
Thailand (n = 128, 19.6%), Indonesia (n = 78, 12.0%), and India
(n = 53, 8.1%). The number of patients coming from Africa
increased as of 2009, with the highest proportion being regis-
tered in 2011 (17.1%). DENV-3 infections were diagnosed after
a stay in West Africa as of 2009, and a ﬁrst DENV case from the
Democratic Republic of the Congo was seen in 2012. The ﬁrst
European destination appeared in 2012, when three patients
acquired dengue after travel to the Autonomous Region of
Madeira, Portugal [9]. In 2012, a remarkable nine of 72 patients
(12.5%) travelled to Suriname, all between March and August.
Identiﬁcation of the serotype by PCR revealed DENV-1 (n = 49,l distribution for the regions Asia, America and Africa for the period
and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 867–872
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(n = 24, 24.5%), DENV-3 (n = 21, 21.4%), and DENV-4 (n = 4,
4.1%) (Table 1). Co-circulation was detected for DENV-1,
DENV-2 and DENV-3 in travellers returning from India as of
2012 and Indonesia in 2013, DENV-1 and DENV-4 in Malaysia
in 2010, and DENV-1 and DENV-3 in Burma and DENV-2 and
DENV-3 in Costa Rica in 2013. All four serotypes were re-
ported in travellers returning from Thailand, but with a
maximum of three in the same year. One co-infection with
DENV-1 and DENV-2 was diagnosed in a patient after travel to
Thailand [7].
Two signiﬁcant increases in dengue incidence attributable to
increases in Asia, the Americas and Africa were seen in 2010
and 2013. In 2010, the number of cases (n = 127) more than
doubled in comparison with the previous year (n = 52) and with
2008, with the highest number of cases since 2002 (n = 56). TheTABLE 1. Distribution of serotypes per country for the period
2002–2013
Region Country Serotype Number
South East Asia Thailand DENV-1 6
DENV-2 3
DENV-3 5
DENV-4 1
DENV-1 + DENV-2 1
Indonesia DENV-1 9
DENV-2 6
DENV-3 2
India DENV-1 4
DENV-2 4
DENV-3 1
Bangladesh DENV-1 3
Burma DENV-1 1
DENV-3 2
Americas Brazil DENV-2 1
Colombia DENV-1 1
Costa Rica DENV-2 1
DENV-3 2
Cuba DENV-2 1
Guatemala DENV-2 1
Nicaragua DENV-1 1
Martinique DENV-1 3
Guadeloupe DENV-1 4
Dutch Antilles DENV-1 1
DENV-2 1
Dominican
Republic
DENV-1 5
Curacao DENV-2 1
Jamaica DENV-1 1
Suriname DENV-2 1
Western Paciﬁc Region Cambodia DENV-3 1
East Timor DENV-3 1
Malaysia DENV-1 1
DENV-4 1
Philippines DENV-1 2
Tahiti DENV-1 1
Vietnam DENV-1 2
DENV-2 1
Laos DENV-3 1
DENV-4 1
Africa Comoros DENV-3 1
DRC DENV-1 1
Burkina Faso DENV-3 2
Ivory Coast DENV-3 1
Mali/Burkina Faso DENV-3 1
Senegal DENV-3 1
Eastern Mediterranean Region Pakistan DENV-2 2
Europe Portugal RAM DENV-1 2
Unknown Unknown DENV-4 1
DENV, dengue virus; DRC, Democratic Republic of the Congo; RAM, Região
Autónoma da Madeira.
Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectannual positivity rate increased from 9.1% to 13.4% (Fig. 1). A
notable peak occurred in patients coming from the French
Antilles (n = 20), with 11 of 20 patients (55%) being diagnosed
in August. PCR revealed DENV-1 in six patients. After a drop in
2011 and 2012, a second increase was registered in 2013, when
the number of cases (n = 139) exceeded that in 2010, and the
annual positivity rate increased from 5.6% to 9.8% (Fig. 1). The
increase occurred especially in July to October. Notable cases
were from Costa Rica (six), the Dominican Republic (seven),
the Democratic Republic of the Congo (four), and Angola
(two). The gender and age distribution in 2010 and 2013 were
comparable with the overall gender and age distribution (data
not shown).DiscussionThis study describes the surveillance of imported DENV in-
fections in Belgium. To our knowledge, most Belgian labora-
tories send their samples for dengue diagnosis to the ITM. Few
laboratories perform a rapid test, and most send positive
samples to the ITM for conﬁrmation, and transfer the epide-
miological and clinical data about the patients. The numbers
given here can therefore be considered to represent the vast
majority of DENV infections in Belgium.
DENV was found to cause an infection in 8.7% of the patients
tested, which makes it the most important arbovirus causing
infections in Belgian travellers, leaving chikungunya and West
Nile virus far behind [10]. The age and gender distribution were
comparable to those reported by others [11–17]. In contrast
to the predominance of DENV-2 described by others [11,13],
the serotype detected most frequently in this study was DENV-
1, probably because of the over-representation of cases from
the French Antilles in 2010 and the Dominican Republic and
Indonesia in 2013.
As PCR was only introduced in the laboratory in 2010, our
data did not allow us to describe the dynamics of the serotypes
during the whole study period. Co-circulation was noted in
countries that have been familiar with this phenomenon for a
long time, such as Thailand, Indonesia, India and Malaysia
[18,19] and Costa Rica (PAHO Situación de Dengue en Centro
América y República Dominicana; 15 July 2013, http://www.
google.be/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad
=rja&uact=8&ved=0CB8QFjAAahUKEwifyYDAoZTGAhXBaR
QKHXMSAMI&url=http%3A%2F%2Fwww.paho.org%2Fcor%2
Findex.php%3Foption%3Dcom_docman%26task%3Ddoc_dow
nload%26gid%3D279%26Itemid%3D263&ei=1RyAVd-KPMHT
UfOkgJAM&usg=AFQjCNFYdIWtFSCnbpVhs32TaRIT1K9hyA
&bvm=bv.96041959,d.d24) and Burma [20], which experienced
an unusually high number of dengue cases in 2013. Co-ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 867–872
CMI Verschueren et al. Dengue surveillance in Belgium 871circulation of different serotypes increases the risk for sec-
ondary infections and co-infections, as was demonstrated in a
traveller to Thailand in 2013 [7].
The emergence of DENV in African countries such as Bur-
kina Faso, Guinea Republic and Senegal in 2009, the Comoros,
Ivory Coast and Mali/Burkina Faso (exact country of exposure
unknown) in 2010, Madeira (Portugal) in 2012 and Angola in
2013 are in line with what has been described by others
[6,21–24]. In 2012 and 2013, DENV infections were registered
in travellers returning from the Democratic Republic of the
Congo, one of which proved to be caused by DENV-1, which,
to our knowledge, has not been described before.
The number of analyses performed increased over the study
period; this was mostly attributable to analyses requested by
external laboratories, probably because of growing awareness
of the disease and familiarity with the diagnostic services offered
by the reference laboratory.
The number of travellers with DENV infections increased
dramatically in 2010 and 2013. Although the number of analyses
performed also increased as of 2010, albeit to a lesser extent, it
is unlikely that the increase in the number of cases was caused
by increasing awareness of the medical staff, as both peaks in
absolute numbers were supported by peaks in positivity rates.
The increase in the number of cases in 2010, and the subse-
quent drop in 2011, are also in line with observations in several
other European countries [11–14,17]. Although several
endemic regions experienced an unusually severe dengue sea-
son in 2013 (ECDC Communicable Disease Threats Report
week 36, http://ecdc.europa.eu/en/publications/Publications/
Communicable-disease-threats-report-01-sep-2013.pdf), an in-
crease in imported cases comparable to that in Belgium has, to
our knowledge, not been reported in other European
countries.
Although the incidence of dengue fever has increased and the
geographical range has expanded enormously over recent de-
cades, the incidence in travellers ﬂuctuated substantially over
the study period. The cyclical pattern of dengue activity has
been reported before, and corresponded to epidemics in single
continents [25]. Both peaks in this study were caused by in-
creases in the numbers of people returning from Asia, the
Americas, and Africa, and probably resulted from a combina-
tion of a higher rate of local transmission at travel destinations
and choice of travel destination and season. Examples are the
high numbers of cases after travel to the French West Indies,
which was hit by its largest outbreak ever in 2010 [26], and to
Suriname in 2012 (http://www.paho.org/hq/index.php?
option=com_docman&task=doc_view&gid=17247&Itemid=).
Apart from the importance of a timely diagnosis of DENV
infection, to provide correct patient care and management,
surveillance allows us to take preventive measures to avoid theClinical Microbiology and Infection © 2015 European Society of Clinical Microbiologyintroduction and transmission of the virus in a new area. DENV
is absent in Belgium. However, one of its vectors, Aedes albo-
pictus, is established in 21 European countries, including
neighbouring France, where three autochthonous cases were
diagnosed in 2010 and 2013 [3,5]. The suitability of the climate
for mosquitoes has signiﬁcantly increased in the Benelux area
during recent decades [27], and A. albopictus was detected in
Belgium in 2000, and again in 2013 [28,29]. Finally, in addition to
the local importance, travellers may serve as sentinels for the
detection of viral activity in tropical areas where surveillance is
limited, such as some African countries [23].
This surveillance has some drawbacks. The study period is
long, and different serological assays have been used over time,
with a possible inﬂuence on the sensitivity of the detection.
PCR and the detection of NS1 antigen were introduced to-
wards the end of the surveillance period, and could have caused
an increase in cases merely because of the use of additional
tools. The introduction of PCR did indeed coincide with the
increase in the number of cases in 2010. However, during that
ﬁrst year, PCR was only used retrospectively on samples that
were proven to be viraemic with serological methods on
follow-up samples. The effect of its introduction can therefore
probably be neglected. In addition, the number of dengue cases
decreased drastically in 2011, when PCR and antigen detection
were introduced in the panel of diagnostic tools that could be
requested by the physician. PCR should indeed be considered
as a complementary diagnostic tool to detect infections earlier
rather than a method with higher sensitivity. On the other
hand, PCR was not performed when the date of fever onset
was missing, and this may have resulted in an underestimation
of the number of DENV infections, as follow-up samples for
detection of seroconversion of antibodies were not sent
consistently.
In conclusion, DENV infections are increasingly being
recognized in import medicine. Travellers should be encour-
aged to protect themselves from mosquito bites, in order to
avoid infections and onward transmission of the virus in new
areas where the vector is established.Transparency declarationThe authors declare no conﬂicts of interest.Author contributionsM. van Esbroeck conceived the study. J. Verschueren, L. Cnops
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